CPRX.NASDAQCatalyst Pharmaceuticals, INC

Form 4: Catalyst Pharmaceuticals Executive Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)

📋All filings for Catalyst Pharmaceuticals, INC
🔒Login to Follow

Steve Miller, Chief Op. & Scientific Officer of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Summary

  • Disposition to the issuer: disposed of 1,093,803 Common Stock, par value $0.001 per share at $31.50 ($34,454,794) on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 180,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 275,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 185,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 146,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 248,004 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 202,958 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 158,454 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 11,873 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 16,534 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 47,826 Restricted Stock Units on July 15, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Steve Miller — Officer (Chief Op. & Scientific Officer)

DateTransactionSecuritySharesPriceValueHeld After
2026-07-15Disposition to the issuerCommon Stock, par value $0.001 per share1,093,803$32$34.5M0
2026-07-15Disposition to the issuerOptions to purchase common stock180,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock275,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock185,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock146,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock248,004——0
2026-07-15Disposition to the issuerOptions to purchase common stock202,958——0
2026-07-15Disposition to the issuerOptions to purchase common stock158,454——0
2026-07-15Disposition to the issuerRestricted Stock Units11,873——0
2026-07-15Disposition to the issuerRestricted Stock Units16,534——0
2026-07-15Disposition to the issuerRestricted Stock Units47,826——0

Key Dates

DateDescription
2026-07-15Disposition to the issuer (1,093,803 shares)
2026-07-15Disposition to the issuer (180,000 shares)
2026-07-15Disposition to the issuer (275,000 shares)
2026-07-15Disposition to the issuer (185,000 shares)
2026-07-15Disposition to the issuer (146,000 shares)
2026-07-15Disposition to the issuer (248,004 shares)
2026-07-15Disposition to the issuer (202,958 shares)
2026-07-15Disposition to the issuer (158,454 shares)
2026-07-15Disposition to the issuer (11,873 shares)
2026-07-15Disposition to the issuer (16,534 shares)
2026-07-15Disposition to the issuer (47,826 shares)

Keywords

insider transaction, Form 4, CPRX, CATALYST PHARMACEUTICALS, INC., neutral, Steve Miller

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.